MINNEAPOLIS (Nov. 30, 2016) – Pharmacogenomics company OneOme announced the addition of Harlan Langstraat, R.Ph., to its growing organization. Langstraat has joined OneOme to assist in business development activities.
Langstraat’s career has included senior management positions in both for-profit and not-for-profit healthcare organizations. Most recently, Langstraat managed the outpatient pharmacies, specialty pharmacy, mail-service pharmacy and retail medical supply businesses at Mayo Clinic, in Rochester, Minnesota. He spent fifteen years at Mayo Clinic before retiring in December 2014.
“As we continue to expand our provider network and establish new distribution channels globally, Harlan’s experience in the development of pharmacy-related businesses will be tremendously helpful,” said OneOme CEO, Paul Owen. “The depth of his experience and knowledge supports our commitment to addressing pharmacy channels as we continue to build provider partnerships.”
Prior to his move to Mayo Clinic, Langstraat held executive positions at Caremark and Quantum Health Resources developing home infusion therapy and specialty pharmacy services.
OneOme is a privately held company backed by early-stage venture firm Invenshure, LLC. It co-developed and exclusively licensed its platform from Mayo Clinic to address the fact that about half of the four billion prescriptions issued each year do not work as intended.
The OneOme RightMed test offers a cost-effective, comprehensive, personalized pharmacogenomic analysis of 22 genes provided as part of routine clinical care. The test helps providers make personalized prescription decisions across more than 340 medications.
In December, OneOme will attend, for the first time, the American Society of Health-System Pharmacists (ASHP)’s midyear clinical meeting and exhibition conference in Las Vegas. More than 20,000 ASHP members will be in attendance, with the goal of improving patient care and medication safety by advancing their knowledge, enhancing skills and learning about the latest pharmacy products and innovations.
While the RightMed test is available globally, OneOme has formal partnerships with High Profile Laboratory in Guaynabo, Puerto Rico, to serve Puerto Rico, Cuba and the Dominican Republic. High Profile Laboratory is an established, specialized provider of clinical and microbiological tests and a partner of Salus, a healthcare provider and a member of the Mayo Clinic Care Network. The company also operates in partnership with Medcan, Canada’s largest executive health clinic, and as recently as September, announced the additions of Minnesota-based Ridgeview Medical Center and Centra Health’s Stroobants Cardiovascular Center in Central Virginia to its provider network.
In addition to the RightMed test, OneOme has also developed a platform for clients to generate the interpretive drug report using genotype or sequence data obtained elsewhere, all with the goal of better identifying which prescription medications may work best for individual patients.
The OneOme platform was co-developed and exclusively licensed from Mayo Clinic to bring pharmacogenomics into routine clinical care. OneOme is a privately held company backed by early-stage venture firm Invenshure, LLC, and Mayo Clinic. To learn more about OneOme, visit www.oneome.com.
Editor’s Note: Mayo Clinic has financial investment in the technology referenced in this news release. The revenue that Mayo Clinic will receive is used to support its not-for-profit mission in patient care, education and research.